ContraFect announces submission of IND application to FDA for CF-370

ContraFect announces that it submitted an Investigational New Drug, IND, application to the U.S. Food and Drug Administration, FDA, on September 15, 2023. The IND application supports a proposed indication for its intravenous antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia, HABP, and ventilator-associated bacterial pneumonia, VABP. “Today’s announcement is an important milestone for our CF-370 program. Globally, there are millions of deaths each year associated with infections caused by antibiotic-resistant Gram-negative bacteria. To be able to advance CF-370, a novel therapeutic candidate with the potential to reduce this seemingly insurmountable burden, into the clinic provides hope for patients suffering and dying in our ICUs every day, many of whom are the most vulnerable from a medical perspective, due to their age, recent surgery or having underlying immunosuppressive conditions,” said Roger Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect. “I want to thank our dedicated employees, our extended team of consultants and our shareholders, for bringing our second program into clinical development. We look forward to initiating Phase 1 First-in-Human studies in the US later this year.”